{"groups":[{"description":"Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\\^2 intravenously on Days 1, 4, 8, 11.","id":"FG000","title":"Vorinostat + Bortezomib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Trial terminated due to slow accrual, only 1 patient registered.","recruitmentDetails":"Recruitment Period: 02/17/09 through 04/26/10. All participants recruited at UT MD Anderson Cancer Center."}